Google
BIIB 株価分析 — BIOGEN INC (Healthcare >> Drug Manufacturers - General)
BIIB に関するよくある質問
BIIBのPER（株価収益率）は？
BIOGEN INC（BIIB）は現在PER 34.77倍で取引されています。
BIIBのROE（自己資本利益率）は？
BIOGEN INCのROEは4.43%です。
BIIBの配当利回りは？
BIOGEN INCの配当利回りは0.00%です。
BIIBの品質スコア（Quality Score）は？
当社のAIはBIIBの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BIIBは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BIIBはどのセクターに属しますか？
BIOGEN INCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NASDAQ市場）
BIIB AI Analysis Summary
Our AI summary for BIIB: BIOGEN INC (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 34.77, ROE of 4.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 202.95
Price
-4.98
(-2.40%)
Day Change
|
|
|---|
BIIB, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
2219
|
| Magic Formula Rank by ROE |
2219
|
| Magic Formula Rank by ROIC |
2246
|
| Price | 202.95 |
| PBV / Sector |
1.63 / 2.68
|
| Earning Per Share | 5.52 |
| PE / Sector |
34.77 / 27.65
|
| PEG or PE/Growth / Sector |
N/A / 0.28
|
| Average 1M Daily Value |
287.96 M
GREAT
|
| Average 1W Daily Value |
268.77 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
58% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:33 |
| Symbol | BIIB |
| Name | BIOGEN INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 147.75 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 30,722.49 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 225 Binney Street, Cambridge, MA, United States, 02142
Phone: 617 679 2000
Website: https://www.biogen.com
Employees: 7,500
Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
